Compounds > atorvastatin
Page last updated: 2024-08-24

atorvastatin and carbostyril

atorvastatin has been researched along with carbostyril in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X1
Corti, N; Hoppe, L; Kovari, H; Maechler, S; Niedrig, D; Russmann, S1
Kulińska, E; Laudy, AE; Tyski, S1
Jones, RD; Li, H; Liao, J; Sun, L; Tong, X; Xu, D; Yang, GY1
Chen, J; Goodin, S; Li, DL; Ma, YR; Ma, YY; Ren, X; Wang, X; Xu, XT; Zhang, K; Zhao, DG; Zheng, X; Zhou, RP1

Other Studies

5 other study(ies) available for atorvastatin and carbostyril

ArticleYear
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
    International journal of oncology, 2014, Volume: 44, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays

2014
Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Atorvastatin; Clonidine; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Humans; Long QT Syndrome; Macrolides; Male; Medication Errors; Middle Aged; Quinolones; Risk Factors; Simvastatin; Tertiary Care Centers; Torsades de Pointes; Young Adult

2016
The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.
    Molecules (Basel, Switzerland), 2017, Jan-11, Volume: 22, Issue:1

    Topics: Acyclovir; Alendronate; Amitriptyline; Anti-Bacterial Agents; Atorvastatin; Dipeptides; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Famotidine; Genes, MDR; Klebsiella pneumoniae; Magnesium Sulfate; Microbial Sensitivity Tests; Nicergoline; Pseudomonas aeruginosa; Quinolones; Salmonella; Ticlopidine

2017
Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53.
    Molecular carcinogenesis, 2019, Volume: 58, Issue:11

    Topics: Animals; Atorvastatin; Carcinogenesis; Cell Line, Tumor; Disease Models, Animal; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; HSP40 Heat-Shock Proteins; Humans; Mice; Molecular Chaperones; Mutant Proteins; Pancreas; Pancreatic Neoplasms; Prenylation; Proto-Oncogene Proteins p21(ras); Quinolones; Tumor Suppressor Protein p53

2019
Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.
    European journal of pharmacology, 2021, Feb-15, Volume: 893

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Quinolones; Signal Transduction; Spheroids, Cellular

2021